Effects of GLP-1 Receptor Agonists on Bile Acid Metabolism and Intestinal Microorganisms: Identification of Association with Nonalcoholic Fatty Liver

Not Applicable

Recruiting

Conditions: Endocrine, nutritional and metabolic disease

Registration Number: KCT0004923

Lead Sponsor: Kyung Hee University Hosipital at Gangdong

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 22

Inclusion Criteria

1) Adults between 20 and 75 years of age diagnosed with type 2 diabetes
2) Patients with poor control of blood sugar level of 7.0% or more of HbA1c even though metformin and sulfone urea were used in combination for more than 2 months
3) Those who voluntarily agreed to participate in the study

Exclusion Criteria

a. If you have a liver disease of a specific cause, such as viral hepatitis, autoimmune hepatitis, alcoholic liver disease
b. Drug users who can affect blood sugar, fatty liver, and gut microflora
(Within 3 months from the study start date)
-Glycocorticoid
-Nonsteroidal anti-inflammatory
-Immunosuppressive
-All kinds of antibiotics
-DPP4 inhibitors
-alpha glucosidase inhibitors
-Probiotics
-Hepatotonics, including UDCA
c. If the laboratory test results below are abnormal
-estimated GFR <30 ml / min / 1.73 m2
d. Drug abuser
e. Pregnant and lactating women
f. People on dialysis for terminal renal failure
g. Beneficiaries of organ transplants, including the liver
h. Those who have undergone surgery to modify the structure of the intestine (eg gastrointestinal resection)
i. 30g men a day, 20g women or more drinkers
j. Those who have received clinical trial drugs within the last 3 months
k. In addition, those judged to be impossible to participate

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in severity of fatty liver

Secondary Outcome Measures

Name	Time	Method
Changes in body mass index, waist circumference and body mass;Comparison before and after treatment of fasting blood glucose, glycated albumin, glycated hemoglobin;internal fat area change;Changes in insulin resistance and secretion;Change of Lipid profile;Change of AST, ALT, Total bilirubin;Change of hs-crp, leptin, adiponectin, TNF-a, IL-6;Change of primary bile acid and secondary bile acid;Comparison of microbial cluster changes in intestinal excretion